Cinclus Pharma: A comment on Phathom’s Q4 report - Redeye

Redeye comments on the Q4 report recently published by Cinclus Pharma’s peer, Phathom Pharmaceuticals. The report signifies the first full year of launch performance for the first PCAB approved in the US, VOQUEZNA. Mainly, the product achieved sales of USD29.7m for Q4, an impressive 81% increase from the previous quarter. We believe that this highlights a growing acceptance and demand for PCABs, which is beneficial for Cinclus and linaprazan glurate.

Länk till analysen i sin helhet: https://www.redeye.se/research/1087344/cinclus-pharma-a-comment-on-phathoms-q4-report?utm_source=finwire&utm_medium=RSS